Phase 4Active, not recruiting

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY)

A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes

Sponsor
Eli Lilly and Company (Industry)
Enrollment
794 enrolled
Conditions
Type 2 Diabetes
Interventions
Tirzepatide; Antihyperglycemic medication
Ages
adults, older adults
Registry
NCT05433584, CTIS2022-501073-40-00, EUCTR2022-000130-42

Full record on ClinicalTrials.gov

From the registry

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

Primary outcomes

  • Change From Baseline in Hemoglobin A1c (HbA1c)

History

  1. Study completion expected

  2. Results posted

  3. Last registry update

  4. Primary completion

  5. Started

  6. Registered